Free Trial

Eli Lilly and Company (LLY) Stock Forecast & Price Target

Eli Lilly and Company logo
$806.14
-12.79 (-1.56%)
(As of 11/4/2024 ET)

Eli Lilly and Company - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
3
Buy
16

Based on 19 Wall Street analysts who have issued ratings for Eli Lilly and Company in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 19 analysts, 3 have given a hold rating, and 16 have given a buy rating for LLY.

Consensus Price Target

$1,008.41
25.09% Upside
According to the 19 analysts' twelve-month price targets for Eli Lilly and Company, the average price target is $1,008.41. The highest price target for LLY is $1,250.00, while the lowest price target for LLY is $723.00. The average price target represents a forecasted upside of 25.09% from the current price of $806.14.
Get the Latest News and Ratings for LLY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Eli Lilly and Company and its competitors.

Sign Up

LLY Analyst Ratings Over Time

TypeCurrent Forecast
11/5/23 to 11/4/24
1 Month Ago
10/6/23 to 10/5/24
3 Months Ago
8/7/23 to 8/6/24
1 Year Ago
11/5/22 to 11/5/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
16 Buy rating(s)
16 Buy rating(s)
17 Buy rating(s)
19 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$1,008.41$977.35$860.05$557.96
Forecasted Upside25.09% Upside10.17% Upside8.42% Upside-1.74% Downside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

LLY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LLY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Eli Lilly and Company Stock vs. The Competition

TypeEli Lilly and CompanyMedical CompaniesS&P 500
Consensus Rating Score
2.84
2.79
2.50
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside24.22% Upside15,701.60% Upside9.90% Upside
News Sentiment Rating
Neutral News

See Recent LLY News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/4/2024Deutsche Bank Aktiengesellschaft
3 of 5 stars
 Lower TargetBuy ➝ Buy$1,025.00 ➝ $1,015.00+25.66%
10/31/2024Barclays
3 of 5 stars
 Lower TargetOverweight ➝ Overweight$1,025.00 ➝ $975.00+16.30%
10/31/2024Bank of America
4 of 5 stars
 Lower TargetBuy ➝ Buy$1,150.00 ➝ $1,100.00+30.87%
10/25/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Verdult
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$1,060.00 ➝ $1,250.00+39.96%
10/17/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Breen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$1,100.00+20.04%
10/10/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$1,000.00 ➝ $1,033.00+11.80%
9/16/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$885.00 ➝ $885.00-4.27%
9/13/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$1,050.00 ➝ $1,100.00+17.67%
9/5/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
U. Raffat
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
8/27/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$1,106.00 ➝ $1,106.00+16.36%
8/16/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$884.00 ➝ $1,030.00+10.89%
8/14/2024Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$1,000.00 ➝ $1,050.00+13.30%
8/9/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$875.00 ➝ $1,000.00+11.94%
8/9/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$1,001.00 ➝ $1,101.00+30.36%
6/24/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$994.00 ➝ $1,015.00+12.98%
5/14/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$770.00 ➝ $840.00+11.04%
4/11/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$650.00 ➝ $723.00-5.02%
4/3/2024Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
2/21/2024DZ Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$820.00+8.50%
10/20/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$612.00 ➝ $710.00+20.28%
8/9/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$490.00 ➝ $580.00+11.20%
8/8/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$490.00 ➝ $580.00+11.20%
7/14/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$560.00+28.82%
6/27/202322nd Century Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
5/1/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$410.00 ➝ $458.00+15.70%
4/28/20233M
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
2/15/2023Societe Generale
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeHold ➝ Sell$278.00-18.41%
12/16/2022Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$384.00 ➝ $410.00+13.93%
12/5/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$390.00 ➝ $430.00+14.74%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 10:47 PM ET.


Should I Buy Eli Lilly and Company Stock? LLY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, October 24, 2024. Please send any questions or comments about these Eli Lilly and Company pros and cons to contact@marketbeat.com.

Eli Lilly and Company
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Eli Lilly and Co:

  • Eli Lilly and Co reported strong quarterly earnings, surpassing analysts' estimates by a significant margin, indicating robust financial performance.
  • The company has a high return on equity of 67.52%, showcasing efficient utilization of shareholder equity to generate profits.
  • Revenue for the quarter exceeded analysts' expectations, demonstrating strong demand for Eli Lilly and Co's pharmaceutical products.
  • Positive analyst ratings and price target upgrades suggest confidence in the company's future growth potential and stock performance.
  • Increased investments by institutional investors and hedge funds indicate a favorable outlook on Eli Lilly and Co's future prospects.

Eli Lilly and Company
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Eli Lilly and Co for these reasons:

  • Market volatility and economic uncertainties could impact the stock price of Eli Lilly and Co, leading to potential short-term fluctuations.

LLY Forecast - Frequently Asked Questions

According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for Eli Lilly and Company is $1,008.41, with a high forecast of $1,250.00 and a low forecast of $723.00.

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and Company in the last twelve months. There are currently 3 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LLY shares.

According to analysts, Eli Lilly and Company's stock has a predicted upside of 25.09% based on their 12-month stock forecasts.

Over the previous 90 days, Eli Lilly and Company's stock had 2 upgrades by analysts.

Analysts like Eli Lilly and Company more than other "medical" companies. The consensus rating score for Eli Lilly and Company is 2.84 while the average consensus rating score for "medical" companies is 2.79. Learn more on how LLY compares to other companies.


This page (NYSE:LLY) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners